Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9561217 | GENENTECH INC | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone |
Jan, 2022
(1 year, 8 months ago) | |
US7767225 | GENENTECH INC | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Sep, 2026
(2 years from now) | |
US7988994 | GENENTECH INC | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Sep, 2026
(2 years from now) | |
US8753679 | GENENTECH INC | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Sep, 2026
(2 years from now) | |
US8420674 | GENENTECH INC | Method of providing pirfenidone therapy to a patient |
Dec, 2027
(4 years from now) | |
US7696236 | GENENTECH INC | Method of providing pirfenidone therapy to a patient |
Dec, 2027
(4 years from now) | |
US7767700 | GENENTECH INC | Method of providing pirfenidone therapy to a patient |
Dec, 2027
(4 years from now) | |
US8383150 | GENENTECH INC | Granulate formulation of pirfenidone and pharmaceutically acceptable excipients |
May, 2028
(4 years from now) | |
US8592462 | GENENTECH INC | Pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(5 years from now) | |
US7635707 | GENENTECH INC | Pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(5 years from now) | |
US8609701 | GENENTECH INC | Pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(5 years from now) | |
US7566729 | GENENTECH INC | Modifying pirfenidone treatment for patients with atypical liver function |
Apr, 2029
(5 years from now) | |
US8754109 | GENENTECH INC | Pirfenidone therapy and inducers of cytochrome P450 |
Jan, 2030
(6 years from now) | |
US8013002 | GENENTECH INC | Methods of administering pirfenidone therapy |
Jan, 2030
(6 years from now) | |
US8648098 | GENENTECH INC | Pirfenidone therapy and inducers of cytochrome P450 |
Jan, 2030
(6 years from now) | |
US7910610 | GENENTECH INC | Methods of administering pirfenidone therapy |
Jan, 2030
(6 years from now) | |
US7816383 | GENENTECH INC | Methods of administering pirfenidone therapy |
Jan, 2030
(6 years from now) | |
US8318780 | GENENTECH INC | Methods of administering pirfenidone therapy |
Jan, 2030
(6 years from now) | |
US8084475 | GENENTECH INC | Pirfenidone therapy and inducers of cytochrome P450 |
Jan, 2030
(6 years from now) | |
US8778947 | GENENTECH INC | Methods of administering pirfenidone therapy |
Aug, 2033
(9 years from now) | |
US10188637 | GENENTECH INC | Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same |
Mar, 2037
(13 years from now) |
Esbriet is owned by Genentech Inc.
Esbriet contains Pirfenidone.
Esbriet has a total of 21 drug patents out of which 1 drug patent has expired.
Expired drug patents of Esbriet are:
Esbriet was authorised for market use on 11 January, 2017.
Esbriet is available in tablet;oral dosage forms.
Esbriet can be used as pirfenidone dose escalation regimen for treatment of fibrosis as 801 mg/day for days 1-7 of the regimen, 1602 mg/day for days 8-14 of the regimen, and 2403 mg/day for at least day 15 of the regimen, discontinuing smoking to avoid reduced pirfenidone efficacy and then administering pirfenidone; discontinuing administration of a strong cyp1a2 inducer to avoid reduced pirfenidone efficacy and then administering pirfenidone, administering pirfenidone concurrently with fluvoxamine, the pirfenidone at a dose of about 801 mg/day to reduce drug interactions with fluvoxamine; modifying pirfenidone administration from a dose of about 2400 mg/day downward by about 1600 mg/day while co-administering fluvoxamine to reduce drug interactions with fluvoxamine, dose escalation over 14 days for treatment of idiopathic pulmonary fibrosis, method for administering pirfenidone to avoid reduced efficacy by discontinuing smoking or by discontinuing or avoiding another strong cyp1a2 inducer, method of administering a granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone as recited in claim 1, to treat idiopathic pulmonary fibrosis, dosage modification following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration, by discontinuing pirfenidone until biomarkers of liver function are within normal limits, then at least 1600mg/day in treatment of ipf; dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by discontinuing pirfenidone until biomarkers are within normal limits, followed by administering at least 1600 mg/day in treatment of ipf; dosage modification following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration, by administering sub-1600 mg/day, following by administering at least 1600 mg/day in treatment of ipf; dosage modification following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration, by administering sub-2400mg/day dose, followed by administering 2403mg/day in treatment of ipf; dosing 2403 mg/day pirfenidone following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration in treatment of ipf; dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by administering sub-1600 mg/day dose, followed by administering at least 1600 mg/day dose in treatment of ipf; dosing of at least 1600 mg/day following grade 2 liver abnormality in biomarker ast and/or alt after pirfenidone administration in treatment of ipf; dosing of at least 1600 mg/day following grade 2 abnormality in liver function biomarker after pirfenidone administration in treatment of ipf; dosage modification following grade 2 abnormality in biomarker ast and/or alt after pirfenidone administration, by discontinuing pirfenidone until biomarkers of liver function are within normal limits, followed by full daily dose in treatment of ipf, dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by discontinuing pirfenidone until biomarkers are within limits, then sub-2400mg/day dose, then full daily dose in treatment of ipf; dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by administering sub-2400mg/day dose then full daily dose in treatment of ipf; dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by administering sub-2400 mg/day dose then full day daily dose in treatment of ipf; dosage modification following grade 2 abnormality in liver function biomarker after pirfenidone administration, by discontinuing pirfenidone until biomarkers are within normal limits, then sub-2400mg/day dose, then full daily dose in treatment of ipf, discontinuing administration of fluvoxamine to avoid drug interactions with pirfenidone and then administering pirfenidone; administering pirfenidone while avoiding co-administration of fluvoxamine to avoid drug interactions with pirfenidone, method for administering pirfenidone to avoid reduced efficacy by avoiding smoking or by avoiding another strong cyp1a2 inducer, administering pirfenidone while avoiding co-administration of a strong cyp1a2 inhibitor to avoid drug interactions with pirfenidone; discontinuing administration of a strong cyp1a2 inhibitor to avoid drug interactions with pirfenidone and then administering pirfenidone, dosage modification in treatment with pirfenidone to reduce drug interactions with ciprofloxacin, administering pirfenidone while avoiding concomitant use of a cyp1a2 inhibitor that is a moderate to strong inhibitor of both cyp1a2 and another cyp enzyme selected from cyp2c9, cyp2c19, and cyp2d6; discontinuing use of a cyp1a2 inhibitor that is a moderate to strong inhibitor of both cyp1a2 and another cyp enzyme selected from cyp2c9, cyp2c19, and cyp2d6 and then administering pirfenidone, continued dosing or dosage modification following elvated liver enzymes in use of pirfenidone, method of administering pirfenidone capsules to treat a fibrotic condition, continued dosing or dosage modification following elevated liver enzymes in treatment of idiopathic pulmonary fibrosis.
The generics of Esbriet are possible to be released after 28 March, 2037.
Drugs and Companies using PIRFENIDONE ingredient
Market Authorisation Date: 11 January, 2017
Treatment: Method of administering pirfenidone capsules to treat a fibrotic condition; Pirfenidone dose escalation regimen for treatment of fibrosis as 801 mg/day for days 1-7 of the regimen, 1602 mg/day for day...
Dosage: TABLET;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic